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1 Executive  Summary 
This report covers international and Australian models for reducing the use of 
ineffective interventions, also described as disinvestment. Disinvestment is a 
development of Health Technology Assessment (HTA). Conventionally HTA has 
focussed on the introduction of new technologies. Although medical technology is 
advancing rapidly, there remain very many technologies in use which have not been 
subject to formal HTA. This has stimulated a growing interest in disinvestment. 
 
This review identified a number of case studies and pilot projects. There is limited 
information available on the mechanisms used, and no rigorous evaluations of their 
impact. The most developed model is that of NICE which has recently embarked on 
providing guidance for disinvestment. A number of technologies have been reviewed; 
but there is limited information available on how these were identified, how 
disinvestment is implemented, or what the effect has been. There is substantial 
resistance to any active disinvestment. Across the various case studies, appraisal of 
candidate technologies seems most likely to be triggered by expert opinion. 
 
In Australia, disinvestment is also generally passive. Technologies may be removed 
from funding or reimbursement if new research demonstrating harms or inefficacy 
becomes public.  More generally, technologies fall into disuse, and are gradually 
replaced by new or improved technologies. Even when guidelines or funding rules are 
changed, there is generally continued use of an existing technology.   
  
This review has found that active disinvestment has generally been removal of funding 
for ineffective and/or unsafe technologies, usually initiated by new evidence of 
inefficacy or harm. Disinvestment is more likely to be passive, ie driven by changes in 
medical practice, as a procedure or treatment gradually falls out of use over time. 
There are very few instances of disinvestment, or appraisal for disinvestment, driven by 
considerations of cost-effectiveness. There are considerable difficulties implementing 
disinvestment in ineffective health care practices. 
 
One area of difficulty is an appropriate mechanism for identifying candidate 
technologies for appraisal. No explicit processes were identified, although there are a 
number of published criteria for prioritising candidates. The US is embarking on a major 
new program of HTA, termed Comparative Effectiveness Research. The list of priority 
topics for appraisal was developed by the Institute of Medicine, using nominations from 
health professionals, consumer advocates, policy analysts and others. The 
development of the candidate topics was a major exercise in itself. Studies of medical 
practice variations can also be used to identify candidate topics for appraisal.  To date, 
there has been relatively little systematic investigation into practice variations in 
Australia. The availability of rich data sets which allow analysis on the basis of small 
areas is essential to research in this field, as is the research capacity to allow rigorous 
analysis.  Program Budgeting and Marginal Analysis is a technique which uses HTA 
methods to drive disinvestment and reinvestment. It is a relatively resource-intensive 
activity, and requires clinicians to identify activities for disinvestment. 
 
Another area of difficulty arises because there are few or no incentives for clinicians in 
disinvestment. Thus reinforces the problems of identifying technologies for appraisal. 
As disinvestment will create losses, to clinicians, to consumers and to providers of the 
technology, there will be strong resistance to any active withdrawal of funding. At the 
same time, the additional benefits and/or savings from any disinvestments may not be 
realised for a considerable period of time and there is a risk that, for some products,  
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interventions or services, cost savings, in particular, may not be realised. This 
increases the cost of pursuing disinvestment. 
 
Both HTA and disinvestment can be seen in a much broader context, that is the 
challenge is to ensure that the additional health spending brings commensurate 
benefits – ensuring health system efficiency. Although there is considerable interest in 
disinvestment, there are problems in identifying which technologies should be 
considered for disinvestment, and strong incentives to retain existing technologies. 
Disinvestment does occur, but generally as a result of existing treatments or other 
interventions falling into disfavour. An alternative approach to proactive disinvestment 
of specific technologies is to encourage more rapid change in medical practice. There 
are various strategies for health care reform which can be categorised as changing 
provider information, such as through the use of clinical guidelines, or the results of 
practice variations studies; changing incentives, though different payments for 
clinicians and other providers, or specifically targeted incentives; changing consumer 
behaviour, by providing more information with or without financial incentives;  or 
changing the structures of health service delivery to provide organisational support and 
incentives for more efficient purchasing of care. 
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2 Introduction 
The NSW Treasury has commissioned, through the Sax Institute, the Centre for Health 
Economics Research and Evaluation (CHERE), University of Technology, Sydney, to 
undertake a literature review of Australian and international models for identifying 
existing health care interventions that are ineffective, and for reducing the use of these 
interventions. This is generally described as ‘disinvestment’, and refers to the formal 
processes and mechanisms which are used to reduce or discontinue the use of 
selected procedures and treatments.  
 
The notion of disinvestment has its origins in Health Technology Assessment. Many 
analyses have concluded that the introduction and dissemination of new health 
technologies are the major driver of increasing health care expenditure. HTA has 
developed a formal approach to analysis and decision making for the introduction of 
new technology (see CHERE report to Treasury Best Practice in Health Technology 
Assessment at the State Level, June 2007). The aim and challenge for HTA is to 
balance the benefits with the risks and costs of new interventions.  The CHERE review 
concluded that best practice HTA would provide appropriate and relevant information 
and be linked to funding or reimbursement decisions. Under such a model, new 
technologies would only be disseminated on the basis of sound evidence of their 
effectiveness and cost effectiveness. In the initial stages of developing HTA, it was 
argued that as new technologies are accepted for funding, then the armamentarium of 
funded technologies will increasingly become more cost-effective, thus improving 
health system efficiency. Now there is substantial experience with HTA over a decade 
or more in several countries. It is clear that new technologies continue to be, on 
balance, cost increasing, albeit justified by increased health benefits. ‘Old” technologies 
continue, often in widespread use, without having been subjected to the same 
evaluation as new technologies. This has stimulated an interest in subjecting existing 
technologies to the same rigorous level of analysis, and removing support for those 
shown to ineffective or less cost-effective. Not surprisingly, the approaches to 
disinvestment in many ways mirror HTA. 
 
The literature review for this project focussed on this brief; and the methods, results 
and conclusions are presented in section 3. The critical issue for implementing a 
disinvestment strategy is not the assessment methodology – that has been well 
established and continues to be refined through conventional HTA – rather it is the 
identification of the candidate technologies for assessment. In section 4, we consider 
other approaches which can be used to identify priorities for assessment. 
 
Both HTA and disinvestment can be seen in a much broader context and this is 
addressed in section 5. While the key concern of the 1970s and 1980s was cost control 
as governments watched rapid increases in total health care spending, over the 1990s 
and 2000s this was replaced with concern for value for money. Increasing personal and 
national wealth, community expectations, longer lifespans and technological advances 
together mean that higher health spending is inevitable; the challenge is to ensure that 
the additional spending brings commensurate benefits – ensuring health system 
efficiency.  
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3 The  literature  on  disinvestment 
3.1 Aims   
The aim of this project is to conduct a review of the international and national literature 
(including grey literature) to identify current practices and describe different approaches 
(if available) for identifying existing health care interventions that are ineffective, and for 
reducing the use of these interventions.  
The review will address the following questions:  
1.  What models (formal structures, processes and mechanisms) have been used in 
Australia and internationally to reduce the use of existing clinical interventions or 
health programs that are ineffective or ineffective relative to their cost (“ineffective 
interventions”)? 
2.  For each model: 
a.  What type of intervention/s does it focus on? 
b.  What methods are used to identify ineffective interventions? 
c.  What mechanisms are used to reduce the use of ineffective interventions? 
(e.g. clinical practice guidelines and policy controls,  eligibility criteria for 
reimbursement payments, funding formulae) 
d.  Is there evidence that the model has reduced the use of specific ineffective 
interventions, with resultant benefits in terms of health outcomes and/or 
costs? 
e.  Is there evidence that the model has resulted in overall benefits in terms of 
health outcomes and/or costs? 
 
3.  What are the common features of successful models, especially in terms of a) - c) 
above? 
4. What challenges would be faced in implementing models that have worked 
elsewhere in the NSW and Australian setting? 
3.2 Method   
The literature was searched to identify studies and reports published between January 
1990 and Aug 2009. Databases of peer-reviewed literature including CINAHL, 
EMBASE, Medline, and PubMed were searched. The bibliographies of all retrieved 
publications were hand searched for any relevant references missing in the database 
searches. The Centre for Reviews & Dissemination database and the EBM Reviews - 
Health Technology Assessment  were also searched. Health technology assessment 
(HTA) organisation websites were also consulted (see Appendix 1).   
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Web-based searches, using the internet search engines ‘Google’ and ‘Google scholar’, 
were conducted to identify national and international reports. Grey literature such as 
conference abstracts and reports were also included.  
3.2.1 Inclusion/selection  criteria 
The following criteria were used for the review and selection of the studies:  
o  published 1990 - 2009  
o available  in  English 
o  specifically focused on disinvestment and ineffective interventions 
o  articles were selected on relevance to the topic 
o  hand searching of relevant articles and reports 
o  relevant Australian and overseas reports/publications known to the researchers 
 
The search history is presented in Appendix 2.  
3.3 Results   
The search identified 36 original papers
1. Of these only seven were relevant to the 
review. These were mainly viewpoints and commentaries on disinvestment. Most of the 
data presented in this report comes from the grey literature, that is, mainly conference 
abstracts and presentations. In this situation, the information is limited to what is 
provided at the meeting (i.e. on the presentation slides). The majority of the 
presentations are dated 2004-onwards with increasing numbers of abstracts identified 
in the last two years.  
The literature review did not identify any formal structures, processes or mechanisms 
that have been developed and used internationally or nationally to reduce the use of 
existing technologies, clinical interventions or health programs that have limited or no 
clinical effectiveness or cost effectiveness. Some HTA agencies and organisations 
have included in their aims the evaluation of ineffective technologies or the need for 
disinvestment as an important process. However few describe the actual process of 
identifying technologies for disinvestment or the guidance to do so. A number of 
publications provide a statement of the problem and the rationale for disinvestment. 
Some pilot studies as well as case studies of specific technologies were identified and 
will be described in this report. All of these were identified in the grey literature, mainly 
conference abstracts and presentations, some discussion papers, and largely covering 
pilot projects and small case studies. As such, there was often insufficient information 
to undertake a formal critical appraisal assessing the quality of these studies.  
                                                 
1 Articles related to Program Budgeting and Marginal Analysis (PBMA) and Cost Effectiveness 
Research (CER) were not identified via this literature review. These are background papers.   
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3.3.1 Definitions 
The term disinvestment is used with a range of meanings and there are different ways 
of examining this concept.  
Elshaug et al defined it as “the process of withdrawing (partially or completely) health 
resources from any existing health care practices, procedures, technologies and 
pharmaceuticals that are deemed to deliver no or low health gain for their cost and thus 
[do] not [represent] efficient health resource allocation” (Elshaug, et al., 2007).   
Disinvestment has also been described as the cessation or restriction of potentially 
harmful, clinically ineffective or cost inefficient practices (Ibargoyen-Roteta, et al., 
2009a). Even though Goodman does not define disinvestment, 
obsolete/outmoded/abandoned technologies are described as those that have been 
superseded or demonstrated to be ineffective or harmful (Goodman, 2004).   
The disinvestment process could also be described as explicit or implicit. Person et al 
identified explicit disinvestment as the process of taking resources from one service in 
order to use them for other purposes (i.e. reallocation of resources) (Pearson and 
Littlejohns, 2007). “Implicit” disinvestment is best described as replacement/updating of 
practice and it occurs when a technology or intervention is superseded and therefore 
falls out of use.   
 
Thus, definitions are diverse and demonstrate that apart from reasons of safety, there 
are no agreed operational criteria for disinvestment.  
3.4 International  Experience 
A recent report on the future of HTA in Europe concluded that there is no evidence that 
disinvestment decisions are actively pursued by HTA agencies. The National Institute 
for Health and Clinical Excellence (NICE) in England and Wales was named as the 
only agency to explicitly recognise the need for disinvestment to be integrated into its 
guidance development (Kanavos, et al., 2008). This literature review however identified 
pilot programs in Denmark and Spain which are discussed below.  
3.4.1  England and Wales 
In England and Wales, decision making regarding the introduction of new and existing 
technologies is led by the Health Technology Assessment process and the National 
Institute for Health and Clinical Excellence (NICE). In 2006 the Department of Health 
announced a new mandate for NICE “to identify and stop ineffective interventions and 
make health services more equitable across the country” (Pearson and Littlejohns, 
2007). NICE guidance applies to England, Wales and Northern Ireland and this 
initiative was expected to free up “millions of pounds” from ineffective or obsolete 
treatments to be reinvested in the NHS (Kmietowicz, 2006).  
Some strategies that NICE has used to identify and stop ineffective interventions 
include: 1) technology appraisals and clinical guidelines aimed at reducing ineffective 
practice (i.e. antibiotics for viral infections) 2) recommendation reminders, highlighting 
existing guidance against the use of ineffective (i.e. home versus hospital 
haemodialysis) 3) commissioning guidelines – effective use of resources/reduce 
spending on ineffective treatments.  
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This later initiative was introduced by NICE in 2007.  Commissioning guidelines are 
web based guides designed to set benchmarks to “determine the level of service 
needed for a particular topic”. They also provide advice on issues such as local needs 
assessment and opportunities for disinvestment (National Institute for Health and 
Clinical Excellence (NICE), 2007).  The first five guides focused on:  
o  Upper gastrointestinal (GI) endoscopy) 
o  Anticoagulation in the treatment of atrial fibrillation 
o  Pulmonary rehabilitation for Chronic Obstructive Pulmonary Disease (COPD) 
o  Assisted discharge schemes for COPD 
o  Assessment of the diabetic foot 
 
The guides collect advice on what to do as well as what not to do. The guide covers 
issues such as:  
 
o  Why commission this service?  
o  What service specification is required to provide an effective service?  
o  What level of service is needed locally?  
o  What resources will be required locally?  
o  What mechanisms are available for target setting, audit, clinical governance, etc?  
 
For example, in relation to the management of COPD the guides state that “the use of 
prophylactic antibiotics is to be discouraged” due to the lack of “robust evidence 
demonstrating a benefit of prophylactic antibiotics in patients with COPD”. Costing tools 
are provided enabling local decision makers to calculate the cost of providing care for 
the predicted number of people with the condition in a local area as well as the cost 
offsets from saved comparator treatment(s). Benchmarks are available in some of the 
tools for setting performance targets, enabling the local health authority to judge 
whether it is under- or over- providing a particular technology or service. An audit 
commission reports on the progress made towards targets by individual local health 
authorities. In contrast to many agencies NICE appears to be more focussed on 
identifying what not to do.   
 
No published data are available to assess the effectiveness or impact of this initiative. 
Information regarding the methods used to identify ineffective technologies as well as 
the mechanisms used to reduce their use is limited. A recent conference presentation 
described some results of the NICE disinvestment pilot project (Garner, 2009). The 
presentation described the areas of disinvestment that NICE has identified into four 
categories:  
 
1.  Relatively ineffective interventions: dilation and curettage for women aged under 
40, grommets, spinal cost stimulation, tonsillectomy. 
 
2.  Largely cosmetic interventions. 
 
3.  Effective interventions with a close benefit/risk balance in mild cases: female genital 
prolapse/stress incontinence, hip, knee joint replacement/revision, wisdom tooth 
extraction.  
 
4.  Effective interventions where cost-effective alternatives should be tried first: carpal 
tunnel, hysterectomy for heavy menstrual bleeding.  
 
Topics that have been the subject of investigation include:  
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o  Bath emollients for atopic eczema –  
o  Grommets for otitis media 
o  Corticosteroids for acute head injury 
o  Lumbar puncture (indication not provided)  
o  Anticoagulants for transient ischaemic attack (TIA) 
o  Low molecular weight heparin (indication not provided) 
o Cervical  screening 
o  Tetracyclines for acne 
o  Topical antibiotics/steroids for acute superficial inflammatory dermatoses 
o  Topical antibiotics for suspected acute bacterial conjunctivitis 
o  Antibiotics for respiratory tract infections (RTIs) 
 
Results from the pilot project showed that there are very few candidates for total 
disinvestment and that new technologies, interventions and practices implicitly replace 
outmoded or old ones (Garner, 2009). It is also acknowledged that while identifying 
topics with disinvestment potential remains a key strand of NICE’s mandate, few 
disinvestment topics are actually referred to NICE, the rationale for referral is not 
explicitly stated in the guidance remit and there is resistance to withdrawing existing 
technologies (Chalkidou, 2009). Furthermore it is recommended that NICE should 
produce more evidence-based disinvestment advice and less budget inflating 
recommendations.  
 
In a qualitative investigation, members of a group of local formulary committees in 
England acknowledged that despite being asked to evaluate existing technologies with 
a view to disinvestment, this was rarely if ever achieved. The stated reasons for this 
were the difficulty in achieving consensus on what to disinvest in and related political 
difficulties, and time and capacity constraints leading to a focus on new technologies 
and as a result the ‘margins’ of health care expenditure (Williams, et al., 2006). 
 
In terms of technology assessment in general, NICE currently uses two models. The 
initial approach adopted by NICE was to undertake multi-technology appraisals, for 
example assessment of a whole class of drugs. The appraisals were based on 
evidence collated by independent evaluators. More recently, and especially for some 
technologies that are considered “breakthrough”, NICE has adopted a single 
technology appraisal process, in which a submission by a sponsor (for example, a 
manufacturer for an individual drug) is evaluated and a recommendation made. The 
multi-technology appraisal approach lends itself more readily to concomitant decisions 
about new investment in technologies and disinvestment in other technologies. For 
example, the process of multi-technology appraisal may identify some technologies 
which are less cost-effective than others and potentially lead to advice to replace these 
technologies with others.  
3.4.2 Denmark 
The Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) 
initiated a pilot project in 2004 to “assess improper use or potentially obsolete 
technologies”. The main focus was on imaging technologies starting with chest x-ray 
(Frellsen and Kristensen, 2005). The rationale for choosing imaging technologies is not 
reported and the information available is limited to a conference abstract where the 
methods were briefly described. The project involved a literature review on the 
effectiveness of routinely performed x-rays, and a questionnaire targeting internal 
medicine units (excluding cardiology and thorax units). The questionnaire asked 
whether the units performed chest x-rays on all patients on admission. A questionnaire  
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directed at radiology units asked if they suspected internal medicine units performed 
routine chest x-rays on all patients at admission. The final outcome was a 
recommendation that chest x-rays should only be performed if there is a specific 
reason. No further information is available regarding this project or its outcomes other 
than that DACEHTA is assessing the use of x-rays of the lower back in younger 
patients (20-49 years).  
3.4.3 Scotland 
The aim of a disinvestment project which began in 2004 in Scotland was to stop and/or 
restrict interventions of low or no health gain. The objectives of the project were to 
understand which interventions were considered for disinvestment, who initiated the 
disinvestment process and what evidence base was used in making a decision. 
Information regarding this project is limited to a conference abstract and no further data 
are available. The initial phase involved a literature review which identified four sentinel 
procedures: grommets, varicose veins, tonsillectomy and dilation and curettage.  The 
second step involved reviewing the National Information Services Division (ISD) in 
relation to the numbers of procedures performed per Health Board, per 100 000 
population.  There was tenfold variation in intervention rates across 12 Health Board 
areas for the identified procedures. Over time, the rates were observed to 
spontaneously trend slowly downwards; limited success was obtained with the 
introduction of guidelines and variance feedback approaches to accelerating these 
rates (Scott, 2006). 
 
The authors concluded that “nobody appears to have responsibility for stopping things 
that do not work or which harm patients (reducing demand)” and that a dedicated 
resource to facilitate this process is required in Scotland. The next step of the project 
was to discuss the results with the Scottish directors of Public Health and Medical 
Directors and set up a Disinvestment Group. However, no further information on the 
progress of this project was able to be identified.  
3.4.4 Spain   
In Spain health technology assessment is undertaken at the provincial level. In 2008 
two provinces (regions) under the auspices of the Health Institute Carlos III (Spanish 
Ministry of Health) undertook a project that aimed to identify, prioritise and assess 
obsolete technologies (Basque Office for HTA, 2008). What follows is the description of 
the work undertaken in these regions.   
3.4.4.1  The Basque Region 
The Basque Office for Health Technology Assessment (OSTEBA) defined potentially 
obsolete technologies (POTs) as “those healthcare technologies or its applications in a 
concrete indication whose clinical benefit, safety, or cost effectiveness has been 
superseded in a significant way by other available alternatives”. (Ibargoyen-Roteta, et 
al., 2009b) The initial literature review and consultation process concluded that there is 
little information about disinvestment strategies and the process for identifying POTs is 
not systematic. Identification of or disinvestment in POTs still relies on expert opinion. 
Ibargoyen-Roteta concluded that identification of POTs is difficult and the process is 
complicated. Health technology evaluation reports and clinical guidelines were  
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described as fundamental in this process. OSTEBA’s work involved four phases 
(Basque Office for HTA, 2008):  
 
1.  Identification process: in this phase obsolete technologies were identified using 
a pilot questionnaire, followed by a literature review and search of the Euroscan 
database.  
2. Selection of variables for prioritisation and evaluation: this was done in 
collaboration with the Galician Agency for Health Technology Assessment 
(avalia-t). 
3.  Case study to test the evaluation tool. 
4.  GuNT Guide elaboration: the development of a hospital guide for investment of 
technologies with proven effectiveness for a determined indication.  
 
So far, progress on three of the four phases is available and summarised below: 
 
1. Technologies identified as worthy of investigation for disinvestment using the pilot 
questionnaire included
2:  
o  Cobalt bomb vs linear multi-energy accelerators 
o  2D LinAcs planning vs 3D LinAcs planning or IMRT 
o Initial Chemotherapy due to waiting lists in radiotherapy treatment vs 
Simultaneous Chemotherapy and Radiotherapy 
o  Non multilaminar accelerators vs Multilaminar accelerators 
o  Patients location only with laser vs Image guided Radiotherapy 
o  Radium vs Iridium 198 
o Cartography  (ineffective)  vs EEG-video or functional MRI 
o  Motor rehabilitation techniques using optometric methods 
 
2. Variables  identified: 
o  General information about the Technology of Interest 
o  The context of the technology 
o  Why is the technology considered obsolete? 
o  Information about costs, effectiveness and safety  
o  Possibility of being eliminated or substituted by an alternative 
 
3.  Case studies selected to test the evaluation tool included: a diagnostic procedure 
(x-ray in cranium encephalic trauma, a program, therapeutic technology (cobalt 
bombs) and a preventative technology  
 
To date the results of this project are yet to be published and information was obtained 
from a conference presentation. Additional information is required to evaluate the 
effectiveness and transferability of this methodology to the NSW context.  
3.4.4.2  Galicia Region  
The main aim of the Galician Agency for Health Technology Assessment (avalia-t - 
Axencia de Avaliación de Tecnoloxías Sanitarias de Galicia) was to develop a method 
to guide people and institutions interested in analysing obsolete technologies in their 
respective health care setting. Avalia-t developed a “prioritisation tool” called PriTec.  
                                                 
2 No information was provided about the indication or condition the technologies were being 
considered for 
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PriTec enables the simultaneous comparison of up to 50 technologies and generates a 
prioritisation report that includes the main results and figures (2009). 
 
Criteria are scored and grouped in the prioritisation areas (domains) associated with 
the monitored technology:  
a) characteristics of the target population/end-users;  
b) risk/benefit; and,  
c) costs, organisation and other implications.  
 
No published data are available to assess the effectiveness or impact of this initiative. 
The tool is freely available on the avalia-t website.  
3.4.5 Australia   
3.4.5.1 National  level   
Two advisory bodies at the National level in Australia are responsible for evaluating 
evidence relating to the safety, effectiveness and cost-effectiveness of new medical 
technologies. The Pharmaceutical Benefits Advisory Committee (PBAC) has 
responsibility for assessment of pharmaceutical products and vaccines for inclusion on 
the National Immunisation Program. The Medical Services Advisory Committee 
(MSAC) assesses health technologies and medical procedures in the private health 
sector (Productivity Commission, 2005). Reimbursement approval for new medical 
technologies, as well as the withdrawal of reimbursement for existing services rests 
with the Minister for Health, under advice from these bodies.  
 
To date several products have been de-listed from the Pharmaceutical Benefits 
Scheme (PBS), largely as a result of new information becoming available about 
effectiveness and safety. Pharmaceutical companies have also voluntarily withdrawn 
products as a result of a newer, more effective one being listed. Therefore the 
disinvestment that occurs in medicines in Australia tends to be implicit, resulting from 
the replacement of current drugs with new, more effective drugs. The 1997-1998 
portfolio budget statements included a plan to de-list medicine items for less serious 
medical conditions from the PBS.  These included a number of medicines that were 
already available over the counter and some others suitable for common ailments such 
as gastro-intestinal problems, anti-inflammatory liniment for pain relief of sprains and 
muscle strains, a number of preparations that were previously prepared by pharmacists 
and two antifungal products (Australian Government Department of Health and Ageing, 
1997). 
 
The PBAC has developed explicit criteria for removing a drug from the PBS (Salked, et 
al., 1999) if: 
 
o  More effective or equally effective but less toxic drug becomes available 
o  Evidence becomes available that the effectiveness of the drug is unsatisfactory 
o  Evidence becomes available that the toxicity or abuse potential of the drug 
outweighs its therapeutic value 
o  The drug has fallen into disuse or is no longer available; or 
o  Treatment with the drug is no longer deemed cost effective relative to other 
therapies.  
  
   19
Disinvestment 
The PBAC has the capacity to review the list of PBS items, including restrictions, 
maximum quantities and number of repeats. It also provides advice about any other 
matters relating to the PBS that are referred to it by the Minister (Australian 
Government Department of Health and Ageing, 2009). 
 
PBAC also has the capacity to implement its own reviews of drugs or classes of drugs, 
which could result in disinvestment.  This review capacity has existed since 2006 but 
as yet has not been used in such a way as to lead to explicit disinvestment decisions.  
 
MSAC has been established to assess new technologies and has not had the capacity 
to initiate its own reviews of existing items. There are no formal delisting criteria. To 
date, delisting has occurred through the Australian Department of Health and Ageing, 
generally as a result of an existing item falling into disuse, a form of natural attrition. 
However, those technologies which have been granted interim approval are 
reconsidered, and the continuation of public funding may not be recommended. 
However in the minutes of an MSAC meeting held in 2006, it was stated that 
“withdrawing a service that is already funded would require evidence that the 
procedure was either unsafe, or not effective (particularly where there are other 
technologies/procedures that are more effective) or well outside the acceptable level of 
cost effectiveness” (Australian Government Department of Health and Ageing, 2006).   
  
In 2001 MSAC recommended that “on the strength of evidence relating to Lung Volume 
Reduction Surgery (LVRS) in advances for advanced emphysema: public funding 
should not be supported for this procedure pending availability of overseas clinical trial 
data expected in 2003”. However as stated in the report up until then LVRS was 
claimed under the Medicare Benefits Schedule (MBS) using the item numbers 38456 
(intrathoracic operation), 38424 (thoracotomy) and 38440 (wedge resection of the lung) 
(Department of Health and Ageing, 2001). This could then be interpreted that claiming 
LVRS on the MBS would no longer be legitimate and therefore a disinvestment 
example. Medicare data do not show any significant drop in the number of services 
claimed under item 38424 for the period January 2000 to December 2004. This 
illustrates how MBS item numbers can be used, so that a similar or closely related 
service can be included unless a very precise item description is given. This is a 
problem for both controlling the dissemination of new services as well as removing 
existing ones.   
 
In the 2009 budget the Australian Government has allocated $9.3 million over two 
years to put in place a new evidence based framework for reviewing services listed on 
the Medicare Benefits Schedule (Department of Health and Ageing, 2009). The 
capacity to undertake these reviews is currently being developed and this may lead to 
a more proactive approach to disinvestment. 
3.4.5.2 State  Level  (VPACT) 
In 2007, the Victorian Department of Human Services and the Victorian Policy Advisory 
Committee on Clinical Practice and Technology (VPACT) held a workshop on the 
future directions for health technology uptake, diffusion and disinvestment in Victorian 
public health services. It was concluded that disinvestment of technologies was of 
interest but a robust framework was lacking. The consensus seemed to be that a 
consultation process would be important to progress this topic (Victorian Department of 
Human Services, 2007). Since then the department has funded a disinvestment 
initiative by Southern Health.   
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3.4.5.3  Area Health Service Victoria - Southern Health 
Southern Health received funding from the Victorian Department of Human Services to 
implement the “Sustainability in Healthcare by Allocating Resources Effectively 
(SHARE) program”. One of the aims of this program is to establish an organisation 
wide evidence based process of decision making and prioritisation for cessation or 
limitation of harmful, ineffective or inefficient procedures. The project started with the 
creation of a steering committee (Victorian Health Newsletter, 2009). The 
disinvestment Subcommittee of the New Technology Committee has the role of 
advising the CEO through the Executive Quality and Safety Committee about which 
devices, procedures and medications should not be used or whose utilisation should be 
changed. Some preliminary work was conducted by Southern Health before funding 
was provided by the department for the SHARE program to be implemented. This 
included two phases. The initial phase involved a systematic literature review to identify 
existing models and seeking information from international and national colleagues 
which is yet to be published and information is limited to an abstract presentation. The 
second phase involved the formulation a project framework.  
As this report was being prepared, Southern Health in conjunction with the Victorian 
Department of Human Services was holding a national workshop to discuss decision-
making around disinvestment in health services (Victorian Health Newsletter, 2009). A 
formal workshop report and the workshop presentation slides will be available on the 
Victorian Department of Human Services website in the future. An informal report on 
the workshop is provided as Appendix 3 (Section 6.3). In summary, most of the 
initiatives presented (as well as the references used during the workshop) had already 
been identified by this project. The workshop highlighted the lack of published data on 
disinvestment and the growing interest in the topic.  
3.4.5.4 Area Health Service New South Wales - Northern Sydney Central 
Coast Area Health Service (NSCCAHS) 
The Northern Sydney Central Coast Area Health Service (NSCCAHS) has instigated 
the Health Technology Evaluation and Approvals initiative.  The aim of the initiative is  
to ensure that decisions regarding the introduction of new (non pharmaceutical) 
medical technologies, and cessation of old ineffective technologies, is guided by 
evidence of effectiveness, safety and cost effectiveness, and a good understanding of 
the organisational impacts of the technologies. The Area Health Service has 
established a committee comprised of consumer representatives, a health economist, 
clinicians and AHS and NSW Health officers. The role of the committee is to make 
recommendations to the NSCCAHS Executive based on their appraisal of the 
application and assessment.  The NSCCAHS has established a clear and simple 
application process and provided resources to conduct an assessment of relevant 
evidence related to each technology under consideration (Gallego, et al., 2009). The 
way the process has been designed, approval for the use of technologies is initiated by 
the individual clinician or clinical group that wishes to adopt the technology. There is no 
requirement to seek approval to cease using an outdated technology and in practice, 
disinvestment relies on changes in clinical practice rather than an explicit assessment. 
3.4.5.5 Other  initiatives 
The ASTUTE health study (Assessing Service and Technology Use to Enhance 
Health) which was funded in 2009 by the NHMRC, aims to trial and evaluate a model to  
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refine the indications for resource allocation to ineffective or inappropriately applied 
health care practices (Elshaug, 2009). Two case studies have been identified for this 
purpose:  
o  Assisted Reproductive Technology (ART) for women over 42 years of age 
o  Upper airway surgical procedures for adult Obstructive Sleep Apnoea (OSA)  
 
As this study has only just commenced, it is too early for results. 
3.4.5.6 Conclusion   
There are few formal mechanisms for undertaking explicit disinvestment activities. 
There are several case studies, and a range of less formal mechanisms, but few health 
authorities have developed active processes. Active disinvestment has generally been 
removal of funding for ineffective and/or unsafe technologies, usually initiated by new 
evidence of inefficacy or harm. Disinvestment is more likely to be passive, ie driven by 
changes in medical practice, as a procedure or treatment gradually falls out of use over 
time. There are very few instances of disinvestment, or appraisal for disinvestment, 
driven by considerations of cost-effectiveness. There are considerable difficulties 
implementing disinvestment in ineffective health care practices which include lack or 
resources for research into established technologies, and inadequate resources and 
lack of political, clinical and administrative will to support the disinvestment process 
(Elshaug, et al., 2007; Pearson and Littlejohns, 2007).   
 
 
In the case of new technologies, there is a clear incentive for initiating an appraisal, 
particularly when the HTA process is linked to funding/reimbursement. For existing 
technologies, new reports of harm or lack of efficacy can initiate an appraisal. 
Otherwise, there is an option value for clinicians and patients in having the technology 
available and funded. It is important to recognise that an active program or strategy of 
disinvestment will create losses, to clinicians, to consumers and to providers of the 
technology. At the same time, the additional benefits and/or savings from any 
disinvestments may not be realised for a considerable period of time and there is a risk 
that, for some products, interventions or services, cost savings, in particular, may not 
be realised. Moreover, the gains from disinvestment are likely to be more diffuse and 
less readily specified than any losses. Hence losers have a stronger incentive to lobby 
for the continuation of the status quo, than gainers do for effecting the change.   
4 Strategies  for  identifying candidate technologies for 
disinvestment  
There are no clearly defined administrative processes for identifying candidate 
technologies for disinvestment, other than new evidence of harm or safety concerns,  
Elshaug et al (2009) suggest criteria by which priorities for disinvestment review might 
be assessed. The challenge for the policy agency is where to start, given the 
thousands of separate interventions currently available. That leads to consideration of 
other means by which appraisal of existing technologies might be triggered. In this 
section we consider the recent US exercise in comparative effectiveness reviews 
(CER) and the development of a list of candidate technologies, research into medical 
practice variations, and PBMA.  
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4.1.1  Comparative Effectiveness Research  
Comparative Effectiveness Research (CER) is the term used to describe the new $1.1 
billion initiative funded in the US as part of the American Recovery and Reinvestment 
Act 2009 (i.e. the fiscal stimulus measures enacted in response to the global financial 
crisis). It will encompass a number of agencies and programs, including developing the 
appropriate skills and expertise in the workforce. Comparative Effectiveness is the 
systematic appraisal of the benefits and risks of alternative treatments and other health 
care interventions (e.g. screening). The inclusion of costs in the appraisal is not explicit. 
Although some have argued that it is implicit and will lead to cost driven decision 
making, others point out that Medicare is prohibited by legislation from considering 
relative costs in the reimbursement decisions (Congress of the United States 
Congressional Budget Office, 2007). 
One component of the program is the development of a list of priority topics. This has 
been completed by the Institute of Medicine, and published in June 2009. The list was 
developed using nominations from health professionals, consumer advocates, policy 
analysts and others. 1268 topics were reduced to the priority list by considering burden 
of disease, variability, gaps in knowledge and the likelihood of improving health. In 
addition to individual interventions, the recommended priority list includes the delivery 
of services and systems of care (Congress of the United States Congressional Budget 
Office, 2007). Thus, the development of the candidate topics was a major exercise in 
itself. 
CER is another term for the HTA processes already used in other countries, including 
Australia, as acknowledged by the Congressional Budget Office (CBO), but relatively 
unrecognised in most of the literature. Similar evaluations have been conducted in the 
US by the Agency for Health Research and Quality (AHRQ). There is no proposal to 
link CER results to funding decisions but rather the provision of this information is 
expected to change clinician behaviour. The experience of other countries and low 
rates of success in using information alone to change clinical practice has not been 
recognised. However, with the additional substantial investment in the US, there will be 
increasing interest in CER (Congress of the United States Congressional Budget 
Office, 2007) 
 
As our previous report HTA pointed out (CHERE, 2008), HTA is most effective when 
linked to funding decisions. The current US situation is particularly volatile; attempts by 
the Obama administration to introduce universal health cover are delicately balanced 
between criticisms of the additional cost of providing more cover and of the move to 
“socialised medicine” where government dictates what treatments doctors may provide. 
 
4.1.2  Research into clinical practice variations 
Variations in the use of health services and per capita expenditure have been observed 
widely, over countries and over time (see CHERE Report to Treasury Variations in 
health care costs and utilisation, 2008). There is evidence for variations across regions 
within a country, but also by insurance status, socio-economic status, medical 
practitioner and delivery organisation (e.g. hospital). Considerable variation in health 
care use is expected and driven by differences in health status. Further variation in the 
use of health services may be due to several factors: 
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o  Differences in the costs faced by patients/consumers  including travel and time 
costs as well as non-reimbursed components of health care fees; 
o  Differences in patient/consumer preferences; 
o  Differences in the availability of health care resources; 
o  Differences in provider behaviour. 
 
Differences in per capita expenditure will be driven by differences in use as well as:  
 
o  Differences in input costs (e.g. labour costs may vary regionally) 
o Differences  in  efficiency. 
 
Variations are problematic for several reasons. Regional variations may represent 
widespread inefficiencies in the health care system, due to the over provision of 
treatment of the provision of ineffective or unnecessary care. There is substantial 
persistent evidence of medical practice variations which are unexplained by health 
need.  
 
There is a large literature which is relevant to understanding and exploring this topic, 
including much clinical and condition specific studies. There is Australian evidence of 
variations in practice across jurisdictions, across Divisions of General Practice, and 
across hospitals. Cross-jurisdictional variations may hide substantial intra-jurisdictional 
variation. However, there has been relatively little systematic investigation into practice 
variations in Australia. The availability of rich data sets which allow analysis on the 
basis of small areas is essential to research in this field, as is the research capacity to 
allow rigorous analysis (Hall, 2008).  Systematic investigations of practice variations 
may identify candidate technologies for disinvestment. 
4.1.3  Program Budgeting and Marginal Analysis 
Program Budgeting and Marginal Analysis (PBMA) is one of a number of frameworks 
designed to incorporate an assessment of the costs and benefits of alternatives within 
a management context of planning and priority setting (other examples are ACE, 
Health Sector Wide Disease Based Model, Health Benefits Group/Health Resource 
Group,). PBMA has been used for over 30 years in the health sector. It was first 
developed in the 1950s and 60s for use in the United States defence force, as a way of 
tabulating expenditure data in different ways to provide information on what was being 
spent and in what manner (Mitton, et al., 2003b). PBMA attempts to pragmatically 
weight research evidence with local data and expert opinion to establish how resources 
are currently being used and how any changes in resource use can be made, through 
redistribution, reduction, or expansion of services (Mitton and Donaldson, 2001). It 
considers both costs and outcomes incurred by alternative uses of limited resources. 
PBMA creates a management process into which results from standard economic 
evaluations and other evidence can be incorporated (Ruta, et al., 2005) by using the 
best available data to estimate the resource costs and outputs for each program. 
Outputs are quantified in terms of readily available measures, for example numbers of 
patients treated or numbers of visits. This step is then carried out across different 
programs and within each program (Viney, et al., 1995). The information requirements 
include:  
•  Activity data which should provide a summary of the services within a given 
period for the program(s) considered.    
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•  Cost data at the service level is particularly important. This data should 
discriminate between the fixed and variable costs of providing a given service. 
This allows the estimation of incremental costs associated with service 
reductions or developments. Of secondary importance is cost data at the 
patient level. This data could also be derived from the literature.  
Benefits or outcomes from services should ideally be obtained from published 
literature. This could include economic evaluations, health technology assessments, 
regional or state policies and guidelines and reports from government health 
departments. When published evidence is not available PBMA may also use expert 
opinion (Peacock, 1998). In some instances primary data collection might be needed 
(Mitton, et al., 2004). Applications of PBMA in health have concentrated on three types 
of program structure, defined by (Peacock and Edwards, 1997):  
•  Service group programs (eg women, the elderly). To date these programs have 
been used in a significant number of PBMA studies. Service or client groups 
are the main focus of the exercise. This provides a clearer focus on health 
gain, however, this approach can create problems when allocating costs from 
different treatment areas.  
•  Specialty based (eg general surgery, orthopaedics). These have been the most 
common PBMA studies (Bate, et al., 2007; Henderson and Scott, 2001; Mitton, 
et al., 2003a). In these studies marginal changes are assessed within a single 
program. According to Peacock the focus of these studies has been on shorter 
term goals, rather than strategic long term planning (Peacock and Edwards, 
1997).   
•  Diseased based programs (eg cardiovascular disease, see for example 
(Carter, et al., 2000; Haas, et al., 2001; Halma, et al., 2004)).One of the 
drawback of the disease based program is that it may be difficult to allocate 
costs to diseases from available local data.  
PBMA is a relatively resource-intensive activity. As such, it requires the commitment 
and cooperation of clinicians and managers, sometimes from competing programs. 
Further, it has been noted that, in the marginal analysis stage of PBMA, activities for 
investment are identified far more readily than are those for disinvestment. Finally, the 
results of a PBMA exercise are able to be implemented most successfully when those 
involved have control of the budget and the means of implementing the decisions 
(Haas, et al., 2008). Indeed, as PBMA relies on clinicians to identify areas of 
disinvestment, there is no incentive for them to do so if the freed resources will be lost 
to them. 
5  Disinvestment and Efficiency - Challenges  
This review of models for disinvestment has not identified any well established 
processes. Although there is considerable interest in disinvestment, there are problems 
in identifying which technologies should be considered for disinvestment, and strong 
incentives to retain existing technologies. Other barriers identified, include scientific, 
political and ethical challenges. Disinvestment does occur, but generally as a result of 
existing treatments or other interventions falling into disfavour. An alternative approach 
to proactive disinvestment of specific technologies is to encourage more rapid change 
in medical practice. This leads to a much broader consideration of current strategies for  
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health care reform which can be categorised as changing provider information, 
changing incentives, changing consumer behaviour, or changing structures. 
5.1  Information to clincians  
The production of guidelines and the results of clinical practice variations may trigger 
policies and strategies to change practice which may include the need to disinvest in 
particular interventions or practices. Guidelines and other approaches of evidence-
based medicine attempt to change clinician behaviour by improving their knowledge. 
Promulgating information about medical practice variations (discussed above) attempts 
to change behaviour by peer comparison. 
 
Clinical practice guidelines are systematically developed statements that assist 
clinicians, consumers and policy makers to make appropriate health care decisions. 
Such guidelines present statements of ‘best practice’ based on a thorough evaluation 
of the evidence from published research studies on the outcomes of treatment or other 
health care procedures. The NHMRC recommends that guidelines should be 
developed by a multidisciplinary committee, the initial tasks of which are to determine 
the need for, and scope of, the guidelines, define the purpose and target audience and 
identify the health outcomes that will improve as a result of their implementation. 
 
In the development of guidelines, it is important to consider both the effectiveness and 
the costs of health care options. In its advice regarding the inclusion of economic 
evidence as part of guideline development, the NHMRC suggests that eliminating 
ineffective clinical practice is good for individuals undergoing health care, but it is also 
good for society, as health care spending is not wasted on ineffective care. Clearly, the 
health of the population may be improved if spending on health care can be directed to 
effective options. Within the context of this report, the overall question is whether 
proposed clinical practice guidelines lead to a more efficient allocation of scarce health 
care resources. Thus, in developing guidelines, the cost (i.e. resource use) as well as 
the effectiveness of the health care options available should be considered, in order to 
ensure: 
 
o  greater health gains for less cost; 
o  the same health gain for less cost; or 
o  greater health gain for an additional cost deemed worth paying. 
 
Implementation and dissemination of guidelines also have resource implications. A new 
clinical practice may cost more than the current practice (e.g. if there is an effective 
health care option for patients who are currently untreated) or less (e.g. if a treatment is 
replaced by a less expensive treatment). Estimating the net cost of the new practice 
also requires some prediction of the success of the guideline in changing practice. 
Unless there is 100% adoption of the proposed practice, the costs of new practice 
patterns will not be the same as the anticipated cost of the guideline practice. There 
may also be a budget constraint that affects the implementation of clinical practice 
guidelines — identifying cost-effective practice per se does not necessarily mean that a 
proposed guideline is affordable within a current budget. For example, it may be that a 
procedure or treatment that is cost-effective when considered against other options on 
a per person basis has to be so widely applied (e.g. as in a population screening 
program) that the costs would exceed the available health care budget. 
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The guideline dissemination process also has associated costs and an economic 
evaluation can be used to analyse alternative strategies of dissemination to determine 
the most cost-effective approach. The total cost of the process is the cost of the 
guideline formulation plus the cost of dissemination and this cost can be compared with 
the costs of changing from current to new practice patterns. The greater the cost 
savings in changing practice, the greater the amount that is worth spending on 
dissemination. The cost-effectiveness of a particular guideline can be assessed by the 
estimated change in health outcomes for the net costs, that is, the cost of development 
and dissemination plus any additional costs of new practice patterns (National Health 
and Medical Research Council (NHMRC), 2001).  
5.2 Incentives  for  clinicans 
There is increasing interest in the use of payment mechanisms to improve health 
system efficiency. The approach can be described as a move away from paying 
clinicians for what they do, do paying for improved health outcomes. The problem is 
that it is difficult to reward better outcomes directly, as there are many influences 
beyond medical care that affect final outcomes and considerable time between the 
medical intervention and the outcome. Thus in practice, incentives have been directed 
towards reinforcing appropriate care. In the UK, this has been implemented through the 
Quality and Outcomes Framework, under which GPs are rewarded for achievement of 
nearly 200 specified indicators. This has had a substantial effect on GP incomes, but 
the evidence on whether it has improved practice and led to better outcomes is 
inconclusive. In the US, such schemes have been implemented in many settings, 
under the description of ‘pay for performance’ or  P4P. Increasingly results are 
becoming available from the evaluation of pilot schemes. This is a rapidly developing 
field of research and would require a separate review project to summarise. 
5.3 Changing  consumer  behaviour 
Another strand of reform approaches emphasises the role of consumers. The objective 
is to make consumers more informed and therefore wiser purchasers of their own care. 
Some schemes are directed towards consumers decision about insurance, but these 
require a competitive insurance market. This is the rationale for the managed 
competition reforms being implemented in the Netherlands, Switzerland and to a lesser 
extent other countries. Other schemes are directed towards consumers’ choice of 
clinician, hospital and/or treatment. One approach is to provide consumers with 
accessible and comparable information on provider performance. The other is to use 
financial incentives, usually higher co-payments, to reinforce the choice of preferred 
providers. Again, there is a substantial field of research and to review it adequately 
would require a separate project. 
5.4  Changing health care structures 
There is also increasing interest in how organizational structures can hinder or facilitate 
health system performance. Organisational structures which are thought to provide 
stronger incentives for purchasing efficient care are the GP as gatekeeper to other 
specialized services, requiring enrollment for primary care to encourage 
comprehensive care and co-ordination, to the idea of a medical home. These  
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organizational structures can also be reinforced by financial incentives, from capitation, 
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6 Appendices   
6.1 HTA  organisations 
Country  Name of the Agency 
ARGENTINA  Institute for Clinical Effectiveness and Health Policy (IECS)   
   
AUSTRALIA  Adelaide Health Technology Assessment (AHTA)   
  Australian Safety and Efficacy Register of New Interventional Procedures – 
Surgical (ASERNIP-S)      
  Medical Services Advisory Committee (MSAC)   
  Pharmaceutical Benefits Advisory Committee (PBAC) 
   
AUSTRIA  Ludwig Boltzmann Institut für Health Technology Assessment 
   
BELGIUM  Belgian Health Care Knowledge Centre 
   
BRAZIL  Departamento de Ciência e Tecnologia (DECIT)  
   
CANADA  Agence d’Evaluation des Technologies et des Modes d’Intervention en Santé 
(AETMIS)    
  British Columbia Office of Health Technology Assessment (BCOHTA) 
  Canadian Coordinating Office for Health Technology Assessment (CCOHTA)  
  Canadian Agency for Drugs and Technologies in Health (CADTH)  includes the 
Common Drug Review (CDR) 
  Ontario Medical Advisory Secretariat & Ontario Health Technology Advisory 
Committee (OHTAC) 
  Program for Assessment of Technology in Health (PATH) 
   
CHILE  Departamento de Economía de la Salud, División de Planificación Sanitaria 
   
DENMARK  Centre for Applied Health Services Research and Technology Assessment, 
University of Southern Denmark, CAST (AP) 
  Danish Institute for Health Services Research (DSI)   
  Danish Institute for Evaluation and HTA (DACEHTA) 
   
FINLAND  Finnish Office for Health Technology Assessment (FinOHTA)   
   
FRANCE  Committee for Evaluation and Diffusion of Innovative Techniques (CEDIT)   
  Haute Autorité de santé (HAS) /French National Authority for Health 
   
GERMANY  German Agency for Health Technology Assessment (DAHTA)   
  The German Institute for Quality and Efficiency in Health Care (IQWIG) 
   
HUNGARY  Unit of Health Economics and Technology Research Assessment (HunHTA) 
   
IRELAND  Interim Health Information and Quality Authority (iHIQA) 
   
ISRAEL  Israeli Center for Technology Assessment in Health Care, The Gertner Institute 
   
ITALY  Agenzia Sanitaria Regionale (ASR) 
  Regione Veneto 
   
LATVIA  Health Statistics and Medical Technologies State Agency (VSMTA) 
   
MEXICO  Centro Nacional de Excelencia Tecnológica en Salud (CENETEC) 
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NETHERLANDS  Health Council of the Netherlands Gezondheidsraad   
  Netherlands Organisation for Health Research and Development (ZonMw)   
   
NEW ZEALAND  New Zealand Health Technology Assessment (NZHTA)   
  The Pharmaceutical Management Agency of New Zealand (PHARMAC) 
   
NORWAY  Norwegian Knowledge Centre for the Health Services (NOKC) 
   
POLAND  Agencja Oceny Technologii Medycznych (AHTAPol), Agency for HTA in Poland 
  Central and Eastern European Society for Technology Assessment in Health 
Care (CEESTAHC) 
   
SPAIN  Agencia de Evaluación de Tecnologías Sanitarias, Instituto de Salud Carlos III / 
Health Technology Assessment Agency (AETS)   
  Andalusian Agency for Health Technology Assessment (AETSA)      
  Catalan Agency for Health Technology Assessment  (CAHTA)   
  Galician Agency for Health Technology Assessment 
  Basque Office for Health Technology Assessment, (OSTEBA) 
  Unidad de Evaluación de Tecnologías Sanitarias, Agencia Laín Entralgo 
   
SWEDEN  Swedish Council on Technology Assessment in Health Care (SBU)   
  Center for Medical Technology (CMT) Assessment, Department of Health and 
Society 
   
SWITZERLAND  Swiss Network on Health Technology Assessment (SNHTA)   
   
UNITED KINGDOM  Health Technology Board for Scotland   
  National Health Service Health Technology Assessment (UK) / National 
Coordinating Centre for Health Technology Assessment (NCCHTA)   
  National Institute for Health and Clinical Excellence (NICE) 
   
UNITED STATES  Agency for Healthcare Research and Quality  (AHRQ)   
  U.S. Blue Cross/ Blue Shield Association (BCBSIL) Technology Evaluation 
Centre (TEC)      
  Veterans’ Affairs Technology Assessment Program (VATAP)   
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6.2 Search  history 
EMBASE, Ovid MEDLINE (R) In-Process, other Non-Indexed Citations, Ovid 
MEDLINE (R) 
1 disinvestment.  mp  70
2 ineffective  intervention$  81
3  1 or 2  151
4  remove duplicates from 3  105









• delist*    
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6.3 Health  technology  disinvestment: test, drugs, clinical prtactice 
- Report of the workshop organised by Southern Health and the 
Victorian Department of Human Services. 
The workshop was held in Melbourne on Thursday the 27
th of August. Associate 
Professor Wayne Ramsey, Executive Director Medical Services and Quality at 
Southern Health introduced the workshop and welcomed the participants who included, 
clinicians, pharmacists, health policy and health service researchers and policy 
makers.  
 
The policy perspective and introduction to the topic was presented by Dr. Adam 
Elshaug and Prof. Janet Hiller from the Adelaide Health Technology Assessment, The 
University of Adelaide. The presenters provided a brief history of disinvestment, the 
challenges faced and international models currently available (some of these have 
already been discussed and are part of the main body of this report). Most details from 
this presentation will soon be published by Elshaug and colleagues. Dr. Elshaug also 
presented results of a case study - airway surgery for obstructive sleep apnea and 
used it as an example of disinvestment at the national level.  After the presentation 
participants gathered in small groups and were asked to discuss the criteria that are 
best suited for identifying and prioritising candidates for disinvestment.  
 
The Health Economics Perspective was presented by Dr. Duncan Mortimer and Prof. 
Anthony Harris from the Centre for Health Economics, Monash University. Dr. Mortimer 
described the problem of allocating funding solely on the basis of effectiveness since 
this implies that ‘money is no object’. Instead there is typically some concern with value 
for money and the trade-off between costs and benefits. He highlighted the role of 
economic evaluation in helping make these trade-offs more explicit so that informed 
choices can be made. He presented the “effectiveness plane” and used three 
hypothetical technologies to describe how economic evaluation can provide useful 
information to guide disinvestment decisions. Results from a discrete choice 
experiment eliciting consumer’s preference for Government investment were also 
presented.  Prof Harris used recently released data from clinical studies on 
vertebroplasty for painful osteoporotic vertebral fractures to illustrate the challenges 
facing disinvestment at the national level in Australia.  
 
The local health service perspective was presented by Dr. Claire Harris and Ian 
Larmour from Southern Health. Dr. Harris presented results from a literature review 
looking at definitions of disinvestment and models. She concluded that there are 
different ways of looking at this concept; for such differences, is that there is no 
absolute measure of or operational criteria for disinvestment. She also described the 
aims of the SHARE report. Mr. Larmour presented results on the Therapeutic 
Evaluation Program (TEP), an initiative by the Pharmacy Department of Southern 
Health. Topics such as changing prescriber behaviour and adherence to guidelines, 
including reports of some initial success were included but are yet to be published.   
 
Panel discussion on decision making in the absence of evidence was facilitated by 
Adam Elshaug and Janet Hiller. The challenge for decision makers is how to balance 
the cost of waiting for better evidence against the cost of acting prematurely. Dr. 
Elshaug presented some results from a qualitative research project exploring decision 
maker’s views on the topic. The discussion then moved to dealing with uncertainty and 
the issue of funding technologies when there is absence of evidence.     
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The final remarks were provided by Richard King from the Centre for Clinical 
Effectiveness, Southern Health.  
 
Small group discussions were held on each one of the topics presented. Results from 
these discussions are not available. The SHARE Team at Southern Health is writing 
the workshop report and this will be available on the Victorian Department of Human 
Services website along with the workshop presentation slides.  
 
In summary most of the initiatives presented (as well as the references used during the 
workshop) had already been identified by the literature review which forms the subject 
of this report. The workshop highlighted the lack of published data on disinvestment 
and the growing interest in the topic. Participants were also asked about the need to 
have a disinvestment annual conference to present results from disinvestment projects 
or to have disinvestment sessions at appropriate conferences. There was also a call for 
a seminar and/or workshop to be held on a yearly basis.   
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